Seattle, United States
MetaGenomika is a biotechnology startup based in the United States, founded in 2022. The company is dedicated to creating AI-powered Molecular Diagnostics for chronic diseases, aiming to leverage the growing availability of genomic and digital data to advance personalized medicine. MetaGenomika’s vision revolves around enhancing diagnostic capabilities for chronic diseases by utilizing cutting-edge technology and knowledge-based systems.
The company's slogan, "A knowledge-based company focused on developing AI-powered Molecular Diagnostics for chronic diseases," underscores its commitment to innovation, leveraging knowledge, and technology to shape the future of healthcare. With a core focus on addressing the diagnostic needs of chronic diseases, MetaGenomika is poised to make significant contributions to the field of biotechnology.
While specific details about its last investment and investors are currently undisclosed, MetaGenomika’s mission aligns with the increasing relevance of predictive and personalized medicine. As the startup continues to advance its AI-powered Molecular Diagnostics, it is poised to attract attention from venture capital firms and investors seeking opportunities in the healthcare and biotechnology sectors.
